hotspot -WSS

hotspot

author：leisure time 2025-09-06 03:33:36 - browse：2

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Failure, not just success, should guide future doctors

WSS

FDA approves Sage Therapeutics’ rapid

Flash flood warnings continue for parts of Missouri, Illinois

Physicians aren't 'burning out.' They're suffering from moral injury

Flash flood warnings continue for parts of Missouri, Illinois

FDA approves Sage Therapeutics’ rapid

NFL doctors' conflicts of interest could endanger players, report says

hotspot

hotspot

focus

Virginia high school admissions case could be legal follow

FDA scientists endorse Pfizer/BioNTech Covid

Peter Hotez and the public health issue of online harassment

A controversial new treatment promises to make little people taller

Guidelines to prevent youth baseball injuries need more muscle

It was time to plan for my old age. If only I could stop crying

Cancer drug shortages should be causing more outrage

Kansas bar where gunfire wounded 9 last month closes permanently

The high cost of giving birth even with insurance

Trump used to be more articulate. What could explain the change?

knowledge

Election results set back Medicaid expansion plans

H.R. 3 is the wrong path to lower drug costs

Alnylam reports growth in sales of rare disease treatments

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

It costs an awful lot of money to give away a kidney

focus

knowledge

hotspot

focus